Til Menge
Affiliations: | Department of Neurology | Heinrich Heine University Düsseldorf, Düsseldorf, Nordrhein-Westfalen, Germany |
Google:
"Til Menge"Mean distance: 17.31 (cluster 55) | S | N | B | C | P |
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Müller-Schmitz K, Krasavina-Loka N, Yardimci T, et al. (2020) Normal Pressure Hydrocephalus Associated with Alzheimer's Disease. Annals of Neurology |
| Christl J, Verhülsdonk S, Pessanha F, et al. (2019) Association of Cerebrospinal Fluid S100B Protein with Core Biomarkers and Cognitive Deficits in Prodromal and Mild Alzheimer's Disease. Journal of Alzheimer's Disease : Jad |
| Menge T, Dubey D, Warnke C, et al. (2016) Ocrelizumab for the treatment of relapsing-remitting multiple sclerosis. Expert Review of Neurotherapeutics |
| Dubey D, Kieseier BC, Hartung HP, et al. (2015) Dimethyl fumarate in relapsing-remitting multiple sclerosis: rationale, mechanisms of action, pharmacokinetics, efficacy and safety. Expert Review of Neurotherapeutics. 15: 339-46 |
| Ruttmann A, Schmidt-Kraepelin C, Zielasek J, et al. (2015) Assessing the Intensity and Frequency of Symptoms of Mental Disorders in Patients with Neurological Disorders European Psychiatry. 30: 415 |
| Menge T, Stüve O, Kieseier BC, et al. (2014) Alemtuzumab: the advantages and challenges of a novel therapy in MS. Neurology. 83: 87-97 |
| Hartung HP, Aktas O, Menge T, et al. (2014) Immune regulation of multiple sclerosis. Handbook of Clinical Neurology. 122: 3-14 |
| Rommer PS, Zettl UK, Kieseier B, et al. (2014) Requirement for safety monitoring for approved multiple sclerosis therapies: an overview. Clinical and Experimental Immunology. 175: 397-407 |
| Teunissen C, Menge T, Altintas A, et al. (2013) Consensus definitions and application guidelines for control groups in cerebrospinal fluid biomarker studies in multiple sclerosis. Multiple Sclerosis (Houndmills, Basingstoke, England). 19: 1802-9 |
| Warnke C, Meyer Zu Hörste G, Menge T, et al. (2013) Teriflunomide for treatment of multiple sclerosis | Teriflunomid zur Behandlung der Multiplen Sklerose Nervenarzt. 84: 724-731 |